newsfilter
← Latest News
GlobeNewswire·

Beam Therapeutics Reports First Quarter 2025 Financial Results and Recent Business Highlights

First Patient Dosed in the Phase 1/2 Study of BEAM-301 in Glycogen Storage Disease Type Ia, Beam's Second Clinical Stage In Vivo Editing Program Updated Data from BEACON Phase 1/2 Clinical Trial of BEAM-101 Accepted for